Shanghai Ailux Biotechnology Co. Ltd. has patented new antibody-drug conjugates consisting of an antibody targeting fibroblast growth factor receptor 2 isoform 2 (FGFR2; FGFR2b) covalently linked to a cytotoxic drug intended for use in the treatment of cancer.
Hangzhou Bio Sincerity Pharma-Tech Co. Ltd. has reported crylamide compounds acting as exportin-1 (CRM1; XPO1) receptor antagonists found to be useful for the treatment of cancer.
The University of California has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase Von Hippel-Lindau disease tumor suppressor (VHL)-binding moiety coupled to cAMP-dependent protein kinase catalytic subunit α (PRKACA) targeting moiety through a linker.
Treeline Biosciences Inc. has disclosed macrocyclic compounds acting as RAS inhibitors that are potentially useful for the treatment of pancreatic cancer (ductal adenocarcinoma) and melanoma.
Impact Therapeutics (Shanghai) Inc. has prepared and tested Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.
Researchers from Takeda Pharmaceutical Co. Ltd. detailed the preclinical characterization of TAK-188, a first-in-class anti-CCR8 antibody-drug conjugate (ADC) designed to selectively target CCR8+ Tregs, alleviating immunosuppression in the tumor microenvironment.
Biolojic Design Ltd. has reported preclinical data for its antibody-drug conjugate (ADC) BD-200, developed using an AI-guided antibody engineering platform named Multibody.
Conventional mouse models are not susceptible to hepatitis A virus (HAV) because murine adaptor protein MAVS is not efficiently cleaved by HAV protease precursors, so intact type I interferon (IFN) signaling blocks productive infection. However, IFN receptor knockout (KO) mice are susceptible to HAV infection and show hallmark features of the infection, having recently been identified as a potential disease model. Researchers from Genematrix Inc. aimed to determine whether nonclinical efficacy studies can be performed in small animal models.
A group led by researchers at Boston Children’s Hospital established a scalable and reproducible model of paclitaxel-induced axon degeneration and neurotoxicity in human induced pluripotent stem cell (iPSC)-derived sensory neurons.
Harbour Biomed has gained IND clearance from the FDA for HBM-7004, enabling the initiation of a first-in-human phase I trial in subjects with advanced solid tumors.
RSS
